Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Advanced Incubation Solution Introduced for Cell-Based Research

By BiotechDaily International staff writers
Posted on 31 Jan 2013
Image: The Thermo Scientific Cytomat 10 automated incubator (Photo courtesy of Thermo Fisher).
Image: The Thermo Scientific Cytomat 10 automated incubator (Photo courtesy of Thermo Fisher).
An automated incubator and storage module provides superior cell growth and assay incubation and a reliable thermal decontamination routine.

Thermo Fisher Scientific (Waltham, MA, USA) has now introduced the new Thermo Scientific Cytomat 10, an automated incubator and storage module designed to provide superior environmental control for cell growth and assay incubations in laboratories performing high-throughput cell biology or screening. The Cytomat 10 provides a fast plate access time of less than 10 seconds. Additionally, multiple transfer positions and an under-bench version allow flexible incubator placement within the laboratory. As the first generation of automated incubator with a fully validated thermal decontamination system, the Thermo Scientific Cytomat 10 is designed to significantly decrease the risk of contamination and reduce assay variability.

Utilizing more than 40 years of experience in CO2 incubator technology, the Thermo Scientific Cytomat 10 design provides scientists with a reliable, robust incubation unit for precious cell cultures and assays. The design virtually eliminates recovery times with a heated automatic access door, with small opening. The efficient thermal disinfection method practically eliminates germs and spore suspensions, even in areas difficult to reach via manual cleaning. Based on the trusted ContraCon Routine of the Thermo Scientific HERAcell incubators, the Cytomat 10’s decontamination is carried out in wet conditions at 90 °C, leaving incubators virtually residue-free. The Thermo Scientific Cytomat 10 incorporates humidity control via an external water reservoir, reducing the risk of contamination from an internal source and the need for repetitive incubator access.

As a flexible incubation unit, the Cytomat 10 incorporates the Thermo Scientific internally automated PSS (Plate Shuttle System) to serve multiple access and loading positions. Cytomat 10 includes an LCD monitor for incubation parameters and full text read-out messaging to inform the user of temperature, humidity, and gaseous atmosphere level changes. The unit can also be seamlessly integrated with existing automated assay hardware.

Related Links:

Thermo Fisher Scientific, Inc.
Thermo Scientific Cytomat 10





Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.